Bogolepova A N, Kovalenko E A, Makhnovich E V, Osinovskaya N A
Pirogov Russian National Research Medical University, Moscow, Russia.
Federal Center of Brain and Neurotechnologies, Moscow, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(9):31-37. doi: 10.17116/jnevro202112109131.
To evaluate the clinical effects of ethylmethylhydroxypyridine malate (Ethoxidol) in patients with chronic cerebral ischemia in an outpatient practice.
60 patients were examined, 58 patients with a diagnosis of cerebrovascular disease (chronic cerebral ischemia) completed the participation in the program. The average age of the patients is 61.2±8.2 years. Neurological complaints typical of patients with chronic cerebral ischemia were recorded. To assess the dynamics of neurological disorders during therapy were used: The Montreal Cognitive Assessment (MoCA), Multidimensional fatigue inventory (MFI-20), Berg Balance Scale (BBS), Tinnitus Handicap Inventory (THI), Clinical Global Impression of Improvement Scale (CGI). The doctors and the patients satisfaction with therapy was assessed using the Visual Analogue Scale (VAS); quality of life - by the VAS of the European Quality of Life Group (EQ-VAS). The course of therapy lasted 60 days. All patients received daily Ethoxidol chewable tablets 400 mg/day (2 tablets (200 mg) in the morning and 2 tablets (200 mg) in the evening).
The results of the observational program showed high efficacy and good tolerability of Ethoxidol in patients with chronic cerebral ischemia. A statistically significant decrease in the severity of the clinical manifestations of chronic cerebral ischemia was noted as early as the 30th day of therapy, followed by maintaining a positive trend until the end of the course of treatment with the drug (60th day). On the therapy, the severity of asthenia, cognitive impairment, dizziness, balance disorders, and tinnitus decreased. There was a decrease in the severity of the condition and the presence of clinical improvement on the CGI scale; there was an increase in the quality of life of patients on the EQ-VAS scale. The majority of the patients and the doctors rated the therapy as effective and safe and were satisfied with it. No serious adverse events were reported.
The data obtained allow us to consider Ethoxidol as an effective drug in the treatment of patients with chronic cerebral ischemia in an outpatient practice.
在门诊实践中评估苹果酸乙甲羟吡啶（乙氧苯柳胺）对慢性脑缺血患者的临床疗效。
对60例患者进行检查，58例诊断为脑血管疾病（慢性脑缺血）的患者完成了该项目。患者的平均年龄为61.2±8.2岁。记录了慢性脑缺血患者典型的神经学症状。为评估治疗期间神经功能障碍的动态变化，使用了：蒙特利尔认知评估量表（MoCA）、多维疲劳量表（MFI-20）、伯格平衡量表（BBS）、耳鸣障碍量表（THI）、临床总体印象改善量表（CGI）。使用视觉模拟量表（VAS）评估医生和患者对治疗的满意度；生活质量——采用欧洲生活质量小组的视觉模拟量表（EQ-VAS）。治疗疗程持续60天。所有患者每天服用400毫克乙氧苯柳胺咀嚼片（早上2片（200毫克），晚上2片（200毫克））。
观察项目结果显示，乙氧苯柳胺对慢性脑缺血患者具有高效性和良好耐受性。早在治疗第30天就注意到慢性脑缺血临床表现的严重程度有统计学意义的下降，随后在药物治疗疗程结束（第60天）前一直保持积极趋势。在治疗过程中，乏力、认知障碍、头晕、平衡障碍和耳鸣的严重程度降低。CGI量表上病情严重程度降低且有临床改善；EQ-VAS量表上患者的生活质量提高。大多数患者和医生将治疗评为有效且安全，并对其感到满意。未报告严重不良事件。
所获得的数据使我们能够将乙氧苯柳胺视为门诊治疗慢性脑缺血患者的有效药物。
